Pancreatic Cancer Peritoneal Metastasis: The Vaccine Landscape in 2026

A comprehensive review of clinical trials, efficacy data, and what it means for patients today

The Scope of the Problem

Pancreatic cancer is the most lethal solid tumor in the world. Its five-year survival rate has hovered around 13% for decades — one of the worst outcomes among all major cancers. For the subset of patients whose disease has spread to the peritoneum — the thin membrane lining the abdominal cavity — the numbers are even more brutal.

Peritoneal metastasis is one of the most common patterns of distant spread in pancreatic ductal adenocarcinoma (PDAC). When cancer cells seed the peritoneal lining, they coat the abdominal wall and organs in tiny tumor nodules, often triggering the accumulation of fluid (ascites) that causes progressive abdominal distension, pain, and nutritional decline. Surgery becomes impossible. Even aggressive intravenous chemotherapy struggles to penetrate the peritoneal compartment at effective concentrations.

The clinical reality is stark: median overall survival for untreated metastatic pancreatic cancer is roughly 3–6 months. Even with first-line chemotherapy, median survival rarely exceeds 9–11 months. The five-year survival rate for metastatic PDAC sits at just 3.2%.

Against this backdrop, researchers have raced to find alternatives — and cancer vaccines have emerged as one of the most talked-about frontiers in pancreatic oncology.

What Is a Therapeutic Cancer Vaccine?

Unlike preventive vaccines (the flu shot, HPV vaccine), a therapeutic cancer vaccine does not aim to prevent disease. Its job is to re-educate the immune system to recognize and attack existing tumors.

The concept is elegant in principle: identify proteins that are either mutated or overexpressed on the surface of cancer cells, present them to T cells, and let the immune system do what it does best — kill what it recognizes as foreign. In practice, pancreatic cancer has historically been classified as an “immunologically cold” tumor, meaning it fails to naturally attract or activate immune effector cells. That coldness is the central challenge that vaccine developers are trying to overcome.

The Four Vaccine Approaches Under Investigation

1. Personalized mRNA neoantigen vaccines

This is the most advanced and most discussed approach. A patient’s tumor tissue or circulating tumor DNA is sequenced, unique nonself mutations (neoantigens) are identified computationally, and a custom mRNA vaccine is manufactured encoding those specific peptides. BioNTech’s BNT122 (autogene cevumeran) is the flagship example. In the landmark Phase 1 trial published by Memorial Sloan Kettering in 2026, half of the 16 post-surgical patients mounted a robust T-cell response — and among those responders, the 4–6 year survival rate reached 87.5%. The caveat: this trial enrolled only post-resection patients in the adjuvant setting. No metastatic patients were included.

2. Multi-peptide vaccines — OSE2101 (Tedopi)

OSE2101 is an “off-the-shelf” peptide vaccine targeting five cancer-associated antigens (CEA, p53, HER2/neu, MAGE-A3, MAGE-A4), designed for HLA-A2–positive patients. It is the only vaccine to have completed a Phase 2 trial in advanced/metastatic pancreatic cancer patients. The TEDOPaM trial (NCT03806309) randomized 107 patients who had progressed-free disease after FOLFIRINOX induction to either FOLFIRI alone or FOLFIRI + OSE2101. At 12 months, OS was 65% vs 61% — the trial met its primary endpoint. But the median OS told a different story: 15.5 months in the vaccine arm versus 17.3 months in the chemotherapy-alone arm. The vaccine combination did not outperform chemotherapy alone in this trial.

3. Whole-cell vaccines — GVAX

GVAX uses pancreatic cancer cells genetically modified to secrete GM-CSF, stimulating a broad immune response. A Phase 2 trial combining GVAX with pembrolizumab and stereotactic body radiation in locally advanced patients (not metastatic) reported a median OS of 21.8 months, with 64.8% of patients deemed potentially resectable after treatment. But again, peritoneal metastasis patients were explicitly excluded.

4. KRAS-targeted peptide vaccines

Since ~90% of pancreatic cancers carry a KRAS mutation, targeting this oncoprotein is an attractive strategy. Johns Hopkins developed a peptide vaccine covering six common KRAS subtypes (G12V, G12A, G12R, G12C, G12D, G13D), tested in combination with dual checkpoint blockade (ipilimumab + nivolumab) in post-surgical patients. In the Phase 1 trial published in Nature Communications (2026), 91.7% of patients mounted a T-cell response to at least one KRAS mutant, and responders showed a median disease-free survival of 29.6 months — but no metastatic patients were studied.

Figure 1 — Clinical landscape of vaccine trials in pancreatic cancer

The Data: Vaccine vs. Standard of Care

To put these numbers in context, here is a head-to-head comparison of survival outcomes across all major treatment strategies in metastatic pancreatic cancer:

Treatment	Trial Setting	Median OS	12-mo OS Rate
BNT122 mRNA vaccine (responders)	Post-surgical (Phase 1)	>48 months	>87.5%
KRAS peptide vaccine (responders)	Post-surgical (Phase 1)	29.6 months	—
GVAX + immunotherapy + SBRT	Locally advanced (Phase 2)	21.8 months	—
OSE2101 + FOLFIRI	Metastatic/advanced (Phase 2)	15.5 months	65%
FOLFIRI alone	Metastatic/advanced (Phase 2)	17.3 months	61%
NALIRIFOX	Metastatic (Phase 3, NAPOLI-3)	11.1 months	45.6%
AG regimen	Metastatic (Phase 3)	9.2 months	39.6%
Daraxonrasib (RAS inhibitor)	RAS-mutant metastatic PDAC (Phase 3)	13.2 months	—

There are two critical truths in this table:

First, vaccine outcomes in early-stage (post-surgical) patients are dramatically better than anything available for late-stage patients — and this is real data, not hype. BNT122 responders showing 87.5% survival at 4–6 years is, by any historical standard, extraordinary.

Second, we cannot yet extrapolate those early-stage results to metastatic patients. The only vaccine that has been tested in a metastatic population (OSE2101) produced results worse than the chemotherapy-only control arm in the same trial. This is not a reason to abandon vaccine research — but it is a reason to be honest about what the data currently shows.

The Peritoneal Metastasis-Specific Challenge

Peritoneal metastasis carries several biological features that make it uniquely resistant to systemic therapy:

• The peritoneal-plasma barrier — Drugs delivered intravenously achieve only a fraction of their plasma concentration in the peritoneal fluid, leaving microscopic tumor nodules on the peritoneal surface underdosed and untreated.

• Immunosuppressive microenvironment — Peritoneal metastases are often surrounded by dense fibrous tissue and immunosuppressive cell populations that physically block effector T cells from infiltrating.

• Rapid clinical deterioration — Malignant ascites, bowel obstruction, infection, and nutritional decline can worsen within weeks, stripping patients of performance status and trial eligibility before they have had a chance to enroll.

The fundamental limitation is data: no published vaccine trial has specifically enrolled or reported results for peritoneal metastasis patients. OSE2101’s TEDOPaM trial included 69% of patients with some distant metastasis — but did not break down outcomes by metastasis site, nor publish a peritoneal subgroup analysis. Until that data exists, physicians and families cannot know whether peritoneal patients derive meaningful benefit from any vaccine approach.

Figure 2 — Survival data comparison across treatment modalities

What About HIPEC and Localized Approaches?

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has demonstrated activity in gastric, colorectal, and ovarian cancers with peritoneal spread. The technique delivers heated chemotherapy directly into the abdominal cavity, exploiting both thermal cytotoxicity and mechanical lavage to eliminate free-floating tumor cells.

In pancreatic cancer with peritoneal metastasis, the evidence base is still thin. HIPEC is technically feasible in selected patients and early-phase data is emerging, but it remains investigational and is almost always combined with CRS — limiting applicability to patients who are still surgical candidates. For the majority of peritoneal metastasis patients who are unresectable, systemic approaches remain the only option.

A more promising direction for immunotherapy in this setting may be intraperitoneal delivery of immune-activating agents — theoretically maximizing local concentration while minimizing systemic toxicity. This concept is being explored in CAR-T and oncolytic virus platforms and may eventually be applicable to vaccine-based approaches as well.

Targeted Therapy: A Parallel Track

While vaccines are being explored, targeted agents are delivering real improvements — particularly in the RAS pathway.

The most significant recent development is daraxonrasib (RMC-6236), a RAS inhibitor from Revolution Medicines that targets the full spectrum of RAS-driven cancers regardless of the specific KRAS mutation subtype. In the Phase 3 RASolute 302 trial (April 2026), daraxonrasib nearly doubled median overall survival compared to standard chemotherapy — 13.2 months versus 6.7 months — with a 60% relative reduction in the risk of death. This result positions RAS inhibitors as a potential backbone for combination strategies with vaccines.

PARP inhibitors (olaparib) remain available for the ~5–7% of patients with germline BRCA mutations after platinum-containing first-line therapy, though the POLO trial showed improvement in progression-free survival without a statistically significant overall survival gain.

These targeted options, while limited in population, reinforce the importance of comprehensive molecular profiling for every metastatic pancreatic cancer patient.

Figure 3 — Molecular targets and vaccine platforms in development

The Combination Strategy: Why Not One or the Other?

The emerging consensus among investigators is that the most promising path forward is not to choose between chemotherapy and immunotherapy — but to combine them strategically.

The rationale is biologically sound: chemotherapy can rapidly shrink tumor burden and modulate the tumor microenvironment in ways that may enhance vaccine immunogenicity. Immunotherapy (checkpoint inhibitors) can remove the brakes on T-cell activity. RAS inhibitors can provide rapid cytoreduction. A vaccine can then establish durable immune surveillance against residual disease.

The hypothetical sequence looks like this:

• RAS inhibitor or chemotherapy drives rapid tumor reduction.

• Vaccine is manufactured and administered during or after cytoreduction, when tumor burden is lowest and immune competence is best preserved.

• Checkpoint inhibitor sustains T-cell activity within the tumor microenvironment.

• Local therapies (radiation, HIPEC) further reduce residual peritoneal disease.

This kind of multi-modality approach has not yet been validated in a randomized trial, but it represents the logical integration of everything currently known about pancreatic cancer biology.

What Should Patients and Families Do Right Now?

The answer is both simple and urgent: act while the disease is stable, not as a last resort.

Therapeutic cancer vaccines have a time lag between administration and measurable clinical benefit. Personalized mRNA vaccines require weeks to manufacture after biopsy. Immune responses take months to translate into survival benefit. A patient with rapidly progressive peritoneal metastasis who waits until third- or fourth-line failure to explore vaccine trials may find themselves ineligible — not because the science isn’t ready, but because their body isn’t ready.

Practical steps to take today:

• Complete comprehensive molecular testing — BRCA1/2, KRAS mutation subtype, MSI/MMR status, HLA typing, and tumor mutational burden. These determine which clinical trials are even accessible.

• Start trial conversations early — As soon as first-line treatment achieves disease control, begin outreach to research centers. Do not wait for chemotherapy to fail.

• Know where to look:

Ruijin Hospital (Shanghai) — mRNA-0217/S001 personalized neoantigen vaccine for advanced PDAC (NCT05916261)

• Peking University Cancer Hospital (Beijing) — EVM16 personalized mRNA vaccine (EVM16CX01), first-in-human study, led by Prof. Shen Lin

• Fudan University Cancer Hospital (Shanghai) — RGL-270 neoantigen mRNA vaccine combined with adebrelimab + mFOLFIRINOX

• Changhai Hospital (Shanghai) — CAR-NK cell therapy for refractory PDAC

• Do not abandon standard care — For physically fit patients, NALIRIFOX and FOLFIRINOX remain the best-evidenced first-line options. The ideal strategy uses chemotherapy to buy time while in parallel exploring vaccine or combination trial eligibility.

Figure 4 — Recommended clinical decision pathway for peritoneal metastasis patients

What’s Coming: The 2026–2028 Horizon

Multiple vaccine trials are actively recruiting or planned:

• BNT122 Phase 2 (NCT05968326) — BioNTech/Roche, expanding the post-surgical adjuvant trial to larger populations globally. While still adjuvant-only, a positive Phase 2 result would pave the way for metastatic cohorts.

• OSE2101 follow-up — Based on the TEDOPaM primary endpoint success, OSE Immunotherapeutics is expected to report longer follow-up data and may explore additional patient populations.

• EVM16 (China) — Everest Medicines’ personalized mRNA vaccine, first-in-human data presented at AACR 2026 with encouraging safety and immunogenicity signals.

• XH001 (China) — The first domestically developed personalized neoantigen vaccine in China, approved by CDE for Phase 1 investigation in 2025.

• RGL-270 (China) — Neoantigen mRNA vaccine launched for Phase 1 in solid tumors (CTR20260513), combining with adebrelimab and chemotherapy.

The technology is advancing rapidly — sequencing is getting cheaper, neoantigen prediction algorithms are improving, and mRNA manufacturing timelines are shortening. What seems out of reach today may become standard of care by the end of the decade.

The Bottom Line

The honest answer to “do vaccines work for peritoneal metastasis?” is: we don’t know yet — because no trial has specifically answered that question.

The complete picture is more nuanced:

• Vaccines have produced extraordinary results in post-surgical patients — but those patients are not the same as peritoneal metastasis patients.

• The only metastatic trial data (OSE2101) showed a vaccine arm that underperformed the chemotherapy control — but that trial was not designed to prove superiority, and the control arm performed surprisingly well.

• Combination strategies — RAS inhibitors + vaccines, chemo + vaccines, checkpoint inhibitors + vaccines — are biologically plausible and are being actively explored.

• Timing matters enormously. Starting the conversation early, while the disease is stable, is the single most important thing a patient or family can do.

The standard of care should not be abandoned without a plan. For physically fit patients, NALIRIFOX and FOLFIRINOX remain the anchors of treatment. Vaccine trials are an addition to, not a replacement for, that foundation.

The science is moving fast. The next 3–5 years will likely produce the first answers that are actually relevant to peritoneal metastasis patients. For now, the smartest strategy is: stay on standard treatment, explore combination and vaccine trials early, and don’t wait for last-line failure to start asking questions.

This article is a comprehensive English summary of a research review on pancreatic cancer vaccine trials originally published by 小胰宝胰腺CIC (May 2026). It is for informational purposes only and should not replace consultation with an oncologist.

---